Assetmark Inc. Grows Stock Position in Structure Therapeutics Inc. (NASDAQ:GPCR)

Assetmark Inc. boosted its position in shares of Structure Therapeutics Inc. (NASDAQ:GPCR) by 120.0% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,318 shares of the company’s stock after buying an additional 719 shares during the quarter. Assetmark Inc.’s holdings in Structure Therapeutics were worth $58,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also bought and sold shares of the company. Driehaus Capital Management LLC grew its holdings in Structure Therapeutics by 3.5% during the 2nd quarter. Driehaus Capital Management LLC now owns 2,577,136 shares of the company’s stock valued at $101,204,000 after purchasing an additional 86,833 shares during the last quarter. Federated Hermes Inc. boosted its holdings in Structure Therapeutics by 6.6% during the 2nd quarter. Federated Hermes Inc. now owns 2,407,206 shares of the company’s stock valued at $94,531,000 after acquiring an additional 150,000 shares during the period. Janus Henderson Group PLC grew its position in Structure Therapeutics by 34.5% in the 1st quarter. Janus Henderson Group PLC now owns 2,076,700 shares of the company’s stock valued at $88,994,000 after acquiring an additional 532,284 shares during the last quarter. Capital Research Global Investors increased its stake in Structure Therapeutics by 56.9% in the first quarter. Capital Research Global Investors now owns 1,527,483 shares of the company’s stock worth $65,468,000 after purchasing an additional 553,948 shares during the period. Finally, RA Capital Management L.P. lifted its position in shares of Structure Therapeutics by 210.2% during the first quarter. RA Capital Management L.P. now owns 1,510,362 shares of the company’s stock worth $64,734,000 after purchasing an additional 1,023,530 shares during the last quarter. Institutional investors own 91.78% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently commented on GPCR shares. JMP Securities reduced their price target on shares of Structure Therapeutics from $91.00 to $86.00 and set a “market outperform” rating on the stock in a research note on Friday, August 9th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $65.00 target price on shares of Structure Therapeutics in a research report on Monday, September 23rd. Finally, Morgan Stanley initiated coverage on Structure Therapeutics in a report on Monday, September 23rd. They issued an “overweight” rating and a $118.00 price target for the company. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, Structure Therapeutics has a consensus rating of “Buy” and an average target price of $86.80.

Structure Therapeutics Stock Down 7.1 %

Shares of NASDAQ:GPCR opened at $31.75 on Tuesday. The company has a market capitalization of $1.82 billion, a price-to-earnings ratio of -42.77 and a beta of -3.23. The firm has a 50 day moving average of $39.38 and a 200 day moving average of $39.80. Structure Therapeutics Inc. has a 52 week low of $26.61 and a 52 week high of $66.38.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.